Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with CD30-positive Hodgkin lymphoma or Non-Hodgkin lymphoma whose cancer has come back after a stem cell transplant using their own cells, or whose cancer has not responded to at least two multi-drug treatment plans and/or an anti-CD30 antibody treatment.
- People newly diagnosed with CD30-positive Hodgkin lymphoma or Non-Hodgkin lymphoma who are unable to receive or complete standard chemotherapy.
- People with a general health and activity score above 60% on standard medical scales (meaning they are able to carry out most daily activities).
- People with an expected survival of more than 12 weeks.
- People whose kidney function is within an acceptable range (creatinine level below 2.5 mg/dl).
- People whose liver enzyme levels are within an acceptable range (no more than 3 times the normal level for ALT and AST).
- People whose bilirubin level (a marker of liver function) is below 2.5 mg/dl.
- People whose blood oxygen level is above 90% while breathing normal room air.
- People with adequate lung function, with key breathing measurements at or above 50% of the expected level (confirm with trial site).
- People whose own immune T cells are available and show at least 10% expression of a specific marker used in this treatment, as confirmed by a laboratory test.
- People, or their legal guardians, who are willing to sign an informed consent form confirming they understand this is a research study and have been told about its possible benefits and risks.
Who may not be able to join:
- People with an active infection such as hepatitis B or C.
- People who have received an anti-CD30 antibody-based treatment within the past 6 weeks.
- People currently using systemic corticosteroids (steroid medicines that affect the whole body).
- People who are pregnant or breastfeeding.
- People who have confirmed tumour involvement in the lungs or gastrointestinal tissues (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Weidong Han, Ph.D, Chinese PLA General Hospital
Phone: 86-10-66937463
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of related adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.